Aegerion Pharma (AEGR) Misses Q2 EPS by 34c
Get Alerts AEGR Hot Sheet
Join SI Premium – FREE
Aegerion Pharma (NASDAQ: AEGR) reported Q2 EPS of ($0.72), $0.34 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $44.5 million versus the consensus estimate of $35.5 million.
For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Weatherford International plc (WFRD) Tops Q1 EPS by 6c
- Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!